CEO: Interest Starting to 'Catalyze'
Second Genome Inks First Microbiome Pharma Deal
By Jennifer Boggs
Wednesday, June 5, 2013
Second Genome Inc. brought on board its first big pharma partner, signing Janssen Biotech Inc. to a multiyear deal focused on using the San Bruno, Calif.-based biotech's microbiome modulation platform to discover drugs for ulcerative colitis.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.